Opinion|Videos|October 11, 2024
Additional Immunotherapies on the Horizon for LS-SCLC
Key Takeaways
- Atezolizumab is being tested in the NRG-LU005 trial for limited-stage SCLC, assessing its efficacy alongside chemoradiation.
- The NRG-LU005 trial is a randomized, phase III study comparing chemoradiation with or without atezolizumab.
Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.
Advertisement
Episodes in this series
Atezolizumab is also being investigated in the NRG-LU005
- What potential role could atezolizumab have in patients with limited-stage disease?
- What is the design of this trial?
- How does the trial design differ from the ADRIATIC trial?
Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?
If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
2
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
3
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
